株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝炎治療薬の世界市場 (2015〜2019年)

Global Hepatitis Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 346664
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
肝炎治療薬の世界市場 (2015〜2019年) Global Hepatitis Drugs Market 2015-2019
出版日: 2015年12月09日 ページ情報: 英文 118 Pages
概要

肝炎とは、肝臓が肝炎水留守に感染することで発症する炎症症状です。主に肝臓がその被害を受けますが、消化器系・頭脳など人体の他の部分にも悪影響を及ぼします。ウイルス感染以外にも、毒物接種やアルコール消費、自己免疫疾患が原因で発症することもあります。各種ワクチンのうち、肝臓病をひきおこすものには、A型・ B型・C型・D型・E型・G型ウイルスがありますが、最も一般的なのはA型〜C型感ウイルスで、急性・慢性感染症の原因となります。世界の肝炎治療薬市場は2014〜2019年にかけて、17.1%の年平均成長率 (CAGR) で成長する見通しです。

当レポートでは、世界の肝臓病治療薬市場について分析し、市場の概要や構造、市場規模の動向 (今後5年間の予測値)、主な上市薬の概要、症状別・作用機序 (MoA) 別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 疾患の概要

  • 疾患についての理解
  • 分類
  • 感染経路
  • 疫学
  • 診断方法
  • 症状
  • 処置の方法

第6章 主な上市薬

  • A型肝炎
  • B型肝炎
  • C型肝炎

第7章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第8章 種類別の市場区分

  • A型肝炎
  • B型肝炎
  • C型肝炎

第9章 作用機序 (MOA) 別の市場区分

  • 対象非限定型薬剤
  • 特定ワクチン向け薬剤

第10章 地域区分

第11章 市場促進要因

第12章 促進要因の影響力

第13章 市場の課題

第14章 促進要因・課題の影響力

第15章 市場の動向

第16章 ベンダー環境

  • 競争シナリオ
  • 主要ベンダー (計7社)
  • その他の有力ベンダー

第17章 主要ベンダーの分析

  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Roche
  • Vertex Pharmaceticals

第18章 付録

  • 略語集

第19章 Technavioについて

図表一覧

目次
Product Code: IRTNTR6912

About hepatitis

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Dynavax Technologies
  • Mitsubishi Tanabe Pharma

Key market driver

  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report

Key market challenge

  • Side-effects of current therapy
  • For a full, detailed list, view our report

Key market trend

  • Collaborations and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Product offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Classification
  • Mode of transmission
  • Epidemiology
  • Diagnosis
  • Symptoms
  • Treatment

PART 06: Key marketed drugs

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C

PART 09: Market segmentation by MOA

  • Virus-specific agents
  • Non-specific agents

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Gilead Sciences
  • Johnson & Johnson
  • F. Hoffman-La Roche
  • Merck
  • GlaxoSmithKline
  • Vertex Pharmaceuticals
  • Novartis
  • Other prominent vendors

PART 17: Key vendor analysis

  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Roche
  • Vertex Pharmaceuticals

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Mode of transmission and incubation period of different types of hepatitis
  • Exhibit 02: Risk factors for hepatitis A transmission
  • Exhibit 03: Risk factors for hepatitis B transmission
  • Exhibit 04: Risk factors for hepatitis C transmission
  • Exhibit 05: Worldwide endemicity of HAV infection
  • Exhibit 06: Endemicity pattern of HBV worldwide
  • Exhibit 07: Prevalence of HBV in APAC
  • Exhibit 08: Acute hepatitis B infection by age group 2005-2013
  • Exhibit 09: Prevalence of hepatitis B in US 2005-2013
  • Exhibit 10: Estimated HBV incidence rates in APAC countries 2004
  • Exhibit 11: Prevalence rates of hepatitis C across different regions 2012
  • Exhibit 12: Antibodies indicating different hepatitis types
  • Exhibit 13: Tests for viral proteins and generic materials
  • Exhibit 14: Screening tests for hepatitis B infection
  • Exhibit 15: Screening tests for hepatitis C infection
  • Exhibit 16: Types of hepatitis and symptoms
  • Exhibit 17: Recommended dosages and schedules for hepatitis A vaccines
  • Exhibit 18: Recommended dosages and schedules for hepatitis B vaccines
  • Exhibit 19: Combination vaccines for hepatitis A and/or hepatitis B
  • Exhibit 20: Hepatitis A: Key marketed vaccines
  • Exhibit 21: Hepatitis B: Key marketed drugs
  • Exhibit 22: Hepatitis C: Key marketed drugs
  • Exhibit 23: Global hepatitis drugs market 2014-2019 ($ billions)
  • Exhibit 24: Five forces analysis
  • Exhibit 25: Market segmentation by type
  • Exhibit 26: Global hepatitis A drugs market 2014-2019 ($ billions)
  • Exhibit 27: Global hepatitis B drugs market 2014-2019 ($ billions)
  • Exhibit 28: Global hepatitis C drugs market 2014-2019 ($ billions)
  • Exhibit 29: Snapshot of global hepatitis drugs market
  • Exhibit 30: Classification of global hepatitis drugs market by MOA
  • Exhibit 31: Global hepatitis drugs market by geographical segmentation 2014
  • Exhibit 32: List of key drivers
  • Exhibit 33: List of key challenges
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: List of key trends
  • Exhibit 36: Gilead: Pipeline candidates for hepatitis B
  • Exhibit 37: Gilead Sciences: Pipeline candidates for hepatitis C
  • Exhibit 38: Gilead Sciences: Key takeaways
  • Exhibit 39: Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
  • Exhibit 40: Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
  • Exhibit 41: Johnson & Johnson: Key takeaways
  • Exhibit 42: Roche: Pipeline candidates for hepatitis C
  • Exhibit 43: F. Hoffman-La Roche: Key takeaways
  • Exhibit 44: Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
  • Exhibit 45: Merck: Pipeline candidates for hepatitis C
  • Exhibit 46: Merck: Key takeaways
  • Exhibit 47: GlaxoSmithKline: Pipeline candidates for hepatitis B
  • Exhibit 48: GlaxoSmithKline: Pipeline candidates for hepatitis C
  • Exhibit 49: GlaxoSmithKline: Key takeaways
  • Exhibit 50: Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
  • Exhibit 51: Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
  • Exhibit 52: Vertex Pharmaceuticals: Key takeaways
  • Exhibit 53: Novartis: Key takeaways
  • Exhibit 54: Gilead Sciences: List of key drugs
  • Exhibit 55: GlaxoSmithKline: Segmentation by product 2014
  • Exhibit 56: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 57: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 58: Johnson & Johnson: Business segmentation
  • Exhibit 59: Johnson & Johnson: Key products of medical devices segment
  • Exhibit 60: Johnson & Johnson: Medical devices segmentation by revenue 2014
  • Exhibit 61: Merck: Business segmentation
  • Exhibit 62: Merck: Geographical segmentation
  • Exhibit 63: Business segmentation by revenue
  • Exhibit 64: Novartis: Business segmentation
  • Exhibit 65: Novartis: Geographical segmentation
  • Exhibit 66: Novartis: Business segmentation by revenue
  • Exhibit 67: Roche: Business segments
  • Exhibit 68: Roche: Pharmaceuticals segmentation
  • Exhibit 69: Roche: Revenue comparison by business segment
  • Exhibit 70: Roche: Geographical segmentation
  • Exhibit 71: Vertex Pharmaceuticals: Product segmentation by revenue
  • Exhibit 72: Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 73: Vertex Pharmaceuticals: Geographical segmentation
Back to Top